Bladder preservation after neoadjuvant therapy for muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study watches people with muscle-invasive bladder cancer who choose to keep their bladder after receiving neoadjuvant therapy (treatment before the main treatment). It aims to see how well bladder-preserving treatments like chemoradiation work over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have bladder cancer that has grown into the muscle layer but has not spread to distant organs.
- You have already received a treatment before the main therapy, such as chemotherapy or immunotherapy.
- You are age 18 or older and in generally good health, able to care for yourself (ECOG score 0–2).
- Your blood counts, liver, and kidney function are good enough to handle chemoradiation.
- You have not had radiation to the pelvic area before, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called nimotuzumab (a type of targeted therapy) added to standard chemoradiation (chemotherapy plus radiation) to treat muscle-invasive bladder cancer without surgically removing the bladder. The goal is to control the cancer while preserving the bladder.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial uses advanced MRI scanning to guide treatment decisions for muscle invasive bladder cancer. It aims to improve outcomes by personalizing therapy based on detailed imaging.
This study tests a combination of bladder-sparing treatments for muscle-invasive bladder cancer, including surgery, chemotherapy, immunotherapy, and radiation, followed by maintenance immunotherapy. The goal is to see if this approach can control cancer while preserving the bladder, compared to a watch-and-wait approach.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This trial tests a bladder-sparing approach for people with muscle-invasive bladder cancer that has a variant histology type. The goal is to avoid removing the bladder by using a combination of treatments.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.